CellWell record HH-79118
Complement blockade: Therapeutic promises and remaining challenges in clinical practice
Gema Fernández-Juárez; Javier Azores-Moreno; Lina León-Machado; Irene Vázquez-Raso; María Soriano-Guillén; Ana Mendoza; María Maldonado; Begoña Rivas Becerra; Cristina Vega Cabrera; Amir Shabaka
2026
In plain language
A review reports C5 blockade with eculizumab improved renal function and survival in atypical hemolytic uremic syndrome, but heterogeneity of complement dysregulation across glomerulopathies limits a uniform therapeutic strategy.
- Evidence
- Emerging
Cite this record: https://thecellwell.org/studies/HH-79118
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.